COVID-19 Public Policy Group Report April 25, 2020
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Masks Off: Officials Reevaluating Mandates for Indoor Mask Use by Leandra Bernstein Monday, May 10Th 2021
Masks off: Officials reevaluating mandates for indoor mask use by Leandra Bernstein Monday, May 10th 2021 WASHINGTON (Sinclair Broadcast Group) — Leading public health figures suggested over the weekend that it was time to reevaluate requirements for wearing masks indoors as COVID-19 cases continue to decline and more than half of all American adults have received at least one dose of a vaccine. On CBS's "Face the Nation" Sunday, former commissioner of the Food and Drug Administration Dr. Scott Gottlieb, encouraged jurisdictions with low rates of infection to begin relaxing mask mandates. "I think we're at the point in time when we can start lifting these ordinances in a wholesale fashion," he said, noting that half the states in the country are seeing daily infections at just 10 per 100,000 and almost a quarter have infection rates of 5 in 100,000. The former FDA chief advocated lifting restrictions on outdoor gatherings entirely and eliminating other required mitigation measures under certain criteria. "The states where prevalence is low, vaccination rates are high, and we have good testing in place—we're identifying infections—I think we could start lifting these restrictions indoors as well, on a broad basis," he said. It's possible that mask ordinances may have to be reimplemented if there are outbreaks or if there is a decline in immunity, Gottlieb advised. "But that's a long ways off. We'll worry about that in the fall and the winter," he said. "We're at the point right now where we could start lifting these ordinances and allowing people to resume normal activity." Asked about Dr. -
Developing and Scaling COVID-19 Vaccines May 13, 2020 at 12:30 – 2:30 Pm ET a Webinar by the Duke-Margolis Center for Health Policy and the Alexandria Summit
Developing and Scaling COVID-19 Vaccines May 13, 2020 at 12:30 – 2:30 pm ET A webinar by the Duke-Margolis Center for Health Policy and the Alexandria Summit Objective: To explore issues, strategies, and policies for developing and scaling COVID-19 vaccines. 12:30 pm Welcome and Overview Mark McClellan, Duke-Margolis Center for Health Policy 12:45 pm Fireside Chat Mark McClellan, Duke-Margolis Center for Health Policy Anthony Fauci, National Institute of Allergy and Infectious Diseases, National Institutes of Health, U.S. Department of Health and Human Services 1:00 pm Envisioning a Path Forward Remarks from Scott Gottlieb, American Enterprise Institute and former Food and Drug Administration, U.S. Department of Health and Human Services 1:05 pm Session One: Vaccine Development This session will explore vaccine development under an accelerated timeline, including strategies to develop or modify technologies, participate in cross-sector collaborations, conduct clinical trials, and achieve approval – all during an active pandemic. Peter Marks, Center for Biologics Evaluation and Research, Food and Drug Administration, U.S. Department of Health and Human Services Tal Zaks, Moderna Therapeutics Adrian Hill, Jenner Institute and Oxford Martin Programme on Vaccines John Reed, Sanofi 1:45 pm Session Two: Vaccine Production and Access at Scale This session will explore the scope and scale of manufacturing needs, once a vaccine has been developed and approved, to prepare for demand and ensure appropriate access. Luciana Borio, In-Q-Tel and former National Security Council Director, Medical and Biodefense Preparedness Paul Stoffels, Johnson & Johnson Richard J. Hatchett, Coalition for Epidemic Preparedness Innovation Victor Dzau, National Academy of Medicine 2:25 pm Closing Remarks Joel Marcus, Alexandria Summit; Alexandria Real Estate Equities, Inc./Alexandria Venture Investments Lynne Zydowsky, Alexandria Summit; Alexandria Real Estate Equities, Inc./Alexandria Venture Investments Mark McClellan, Duke-Margolis Center for Health Policy 2:30 pm Adjourn . -
Rb-Annual-Report-2012.Pdf
Reckitt Benckiser Group plc Reckitt Benckiser Group Healthier Happier Annual Report and Financial Statements 2012 Stronger Reckitt Benckiser Group plc Annual Report and Financial Statements 2012 Contents 1 Chairman’s Statement 2 Chief Executive’s Statement 10 Business Review 2012 18 Board of Directors and Executive Committee 19 Report of the Directors 22 Chairman’s Statement on Corporate Governance 24 Corporate Governance Report 30 Statement of Directors’ Responsibilities 31 Directors’ Remuneration Report 38 Independent Auditors’ Report to the members of Reckitt Benckiser Group plc 39 Group income statement 39 Group statement of comprehensive income 40 Group balance sheet 41 Group statement of changes in equity 42 Group cash flow statement 43 Notes to the financial statements 75 Five-year summary 76 Parent Company – Independent Auditors’ Report to the members of Reckitt Benckiser Group plc 77 Parent Company balance sheet 78 Notes to the Parent Company financial statements 84 Shareholder information Chairman’s Statement largest consumer health care category in The Board conducted its regular reviews the world with the acquisition of Schiff of the Company’s brands, geographic area Nutrition International, Inc. (Schiff) and and functional performance together with its leading US brands in the vitamins, detailed reviews of its human resources. minerals and supplements market. There The Board also completed its annual were also a few disposals of non core assessment of corporate governance assets. Net debt at the end of 2012, after including Board performance, corporate paying for dividends, net acquisitions and responsibility, and reputational and organisation restructuring, stood at business risk. £2,426m (2011: £1,795m). AGM Resolutions Your Board proposes an increase in the final The resolutions, which will be voted dividend of +11%, taking it to 78p per upon at our AGM of 2 May 2013 are share, and bringing the total dividend for fully explained in the Notice of Meeting. -
Betterbusiness Betterfinancials How We Drive Growth and Outperformance
Reckitt Benckiser Group plc Annual Report and Financial2015 Statements betterbusiness 2015 Reckitt Benckiser Group plc (RB) Annual Report and Financial Statements We make a difference to people’s lives through a trusted portfolio of brands, across consumer health, hygiene and home. Our vision Our purpose A world where people are To make a difference, by healthier and live better. giving people innovative solutions for healthier lives and happier homes. Our strategy betterbusiness betterfinancials How we drive growth and outperformance Chief Executive’s Review on pages 8–9 bettersociety betterenvironment How we support How we reduce our communities and our environmental develop our people impact Strategic framework on pages 12–13 Contents Strategic Report bettersociety Governance Report 1 Highlights 24 – Workplace 46 Board of Directors 2 At a glance 26 – Communities 50 Executive Committee 4 Chairman’s Statement 26 – Products 52 Chairman’s Statement on 7 Reasons why RB delivers betterenvironment Corporate Governance 8 Chief Executive’s Review 27 – Greenhouse gas emissions 54 Corporate Governance Statement 10 Our unique culture 28 – Water 60 Nomination Committee Report 12 Strategic framework 28 – Waste 61 Audit Committee Report 14 Our market and resources 29 – Sourcing 66 Directors’ Remuneration Report betterfinancials 30 Our operating model 68 Our remuneration at a glance 16 – Our strategy to deliver 32 Our operating model in action 70 Annual Report on Remuneration 17 – Organisation 34 Creating stakeholder value 79 Directors’ Remuneration Policy 19 – Powermarkets 36 Financial Review 85 Report of the Directors 20 – Powerbrands 40 Strategic Risks 88 Directors’ Statement of Responsibilities 22 – Virtuous earnings model Financial Statements 89 Financial Statements Any information contained in the 2015 Annual Report and Financial Statements on the price at which shares or other securities in Reckitt Benckiser Group plc have been bought or sold in the past, or on the yield on such shares or other securities, should not be relied upon as a guide to future performance. -
Sustainable Chemicals Management: Tools and Trends
Sustainable Chemicals Management: Tools and Trends November 18, 2015 Today’s topics and speakers Cheryl Baldwin VP of Consulting Pure Strategies Jennifer Duran Global Head of Sustainable Better Ingredients Case Study Innovation RB Bob Kerr Chemicals Management Software Co-Founder & Principal Review Pure Strategies Tim Greiner The Chemical Footprint Project & Co-Founder & Managing Director Market Trends Pure Strategies 2 Key session logistics • All attendees in listen-only mode • Use chat window for questions – during and after presentations • Some attendee-response questions – respond in chat window • Webinar is being recorded • Recorded webinar and slides-only version at www.purestrategies.com shortly after webinar 3 Pure Strategies overview • Founded 1998 – 17 years providing sustainability expertise to leading companies. • Deep experience working with: ◦ Sustainability leaders and those at earlier stages of sustainability pathway ◦ Iconic brands and less widely known companies ◦ Mix of B2C and B2B companies ◦ Food & beverage ◦ Consumer products ◦ Retail ◦ Life sciences www.purestrategies.com 4 Pure Strategies areas of expertise 5 Partial client list Today’s topics and speakers Cheryl Baldwin VP of Consulting Pure Strategies Jennifer Duran Global Head of Sustainable Better Ingredients Case Study Innovation RB Bob Kerr Chemicals Management Software Co-Founder & Principal Review Pure Strategies Tim Greiner The Chemical Footprint Project & Co-Founder & Managing Director Market Trends Pure Strategies 7 Sustainable Chemicals Management • Addressing chemicals of concern • Improving health and • Evaluating and verifying environmental profile composition • Enhancing transparency and collaboration 8 Sustainable Chemicals Management Why are companies enhancing the safety and transparency of chemicals and materials in their products and supply chains? A. Meet regulatory requirements B. -
Enterprise Report Restoring Liberty, Opportunity, and Enterprise in America
Issue No. 3, Summer 2021 Enterprise Report Restoring Liberty, Opportunity, and Enterprise in America AEI, Reopening By Robert Doar The hot summer is here in Washington and with it, at long last, a return to the way our building on Massachusetts Avenue should always be. Scholars and public officials are gathering for meals and meetings. Students are assembling for classes conducted by the best public intellectuals in America. The halls are alive with talk of how we can advance the promise of the United States with policies that promote individual freedom, family, faith, and the benefits of work and free and open markets. Like many of you, throughout much of the past year, AEI scholars and staff became experts in Zoom and found new ways to stay connected with our wider community. For the most part, some members of AEI’s senior team and I were at our desks here in the D’Aniello Building, but it was a pretty empty space. Thankfully, our scholars, research assistants, and business and outreach teams working remotely continued to lead the most important debates facing our nation. Some of the great work our scholars produced during this unprecedented time includes Scott Gottlieb’s bipartisan leadership on our pandemic response (including his 66 consecutive appearances on Face the Nation); Michael R. Strain’s crucial role in designing and implementing the Paycheck Protection Program, which helped save millions of jobs; Frederick M. Hess’ launch of the Conservative Education Reform Network, which is planting the intellectual seeds for meaningful reform in school systems nationwide; Kori Schake’s revitalization of the AEI defense team, including the creation of the Defense Futures Simulator and the addition of a leading national security scholar, Klon Kitchen; and Yuval Levin, Matthew Continetti, and Adam J. -
ACP Letter to Senate Leaders Highlighting Support for Sections
June 2, 2020 The Honorable Mitch McConnell The Honorable Charles Schumer Majority Leader Minority Leader United States Senate United States Senate Washington, DC 20510 Washington, DC 20510 Dear Majority Leader McConnell and Minority Leader Schumer: On behalf of the American College of Physicians (ACP), I am writing to urge the Senate to consider additional legislation to respond to the economic devastation and public health care crisis caused by the COVID-19 pandemic. Unless the Senate acts soon, the ability of our nation’s internal medicine physicians to provide continuous and comprehensive health care to adults including elderly patients at most risk to infection from COVID-19 remains at risk. Several weeks ago, ACP submitted a letter to Senate leaders that provided our recommendations for the Senate to act on legislation to address this crisis. Many of these policies were included in H.R. 6800, the HEROES Act that was passed by the House. We urge the Senate to adopt these policies included in the HEROES Act which include: Additional emergency funding to help struggling physician practices keep their doors open by partially offsetting revenue losses and increased expenses relative to COVID- 19; Improvements in the Medicare Accelerated and Advance Payment Program; Support for the COVID-19 response workforce by expediting visas for international medical graduates (IMGs) to enter the U.S. for training and patient care, permanently authorizing the Conrad 30 Program, and providing a pathway for IMGs and their families already in the U.S to obtain permanent residency status; Expansion of coverage and increases federal funding for Medicaid; and Funding for the infrastructure and health system capacity needed to rapidly expand testing and contact-tracing, thereby enabling economic, social and medical care activities to gradually resume on a prioritized basis while mitigating transmission and deaths from COVID-19. -
Scott Gottlieb, M.D
WORLDWIDE SPEAKERS GROUP LLC YOUR GLOBAL PARTNER IN THOUGHT LEADERSHIP SCOTT GOTTLIEB, M.D. Scott Gottlieb, MD is a practicing physician and the 23rd Commissioner of Food and Drugs. A leading expert in health policy, Dr. Gottlieb’s work focuses on providing insights into the economic and technological forces driving the transformation of healthcare. From 2005-2007, Dr. Gottlieb served as FDA Deputy Commissioner for Medical and Scientific Affairs and before that, from 2003-2004, as a senior advisor to the FDA Commissioner and as the FDA’s Director of Medical Policy Development. He left FDA in the spring of 2004 to work on implementation of the new Medicare Drug Benefit as a Senior Adviser to the Administrator of the Centers for Medicare and Medicaid Services, where he supported policy work on quality improvement and the agency’s coverage process, particularly related to new medical technologies. Dr. Gottlieb is the author of more than 300 articles that have appeared in leading medical journals as well as The Wall Street Journal, The New York Times, USA Today and Forbes Magazine. Dr. Gottlieb has held editorial positions on the British Medical Journal and the Journal of the American Medical Association and appears regularly as a guest commentator on the cable financial news channel CNBC. He is an invited contributor to POLITICO.com, an editorial board member of the journal Value Based Cancer Care, the Food and Drug Law Institute’s Policy Forum, and is a member of the board of advisers of Cancer Commons. Dr. Gottlieb also serves as an advisor to the National Comprehensive Cancer Network, and a member of NCCN’s working groups. -
Mark B. Mcclellan, M.D., Ph.D. Duke University 100 Fuqua Drive Box 90120 Durham N.C
CURRICULUM VITAE MARK B. MCCLELLAN, M.D., PH.D. DUKE UNIVERSITY 100 FUQUA DRIVE BOX 90120 DURHAM N.C. 27708 EDUCATION: 1993 Ph.D., Economics, Massachusetts Institute of Technology 1992 M.D., Harvard-MIT Division of Health Science and Technology, cum laude 1991 M.P.A., Regulatory Policy, Kennedy School of Government, Harvard University 1985 B.A., English/Biology, University of Texas, Austin, summa cum laude CLINICAL TRAINING: 1996 Diplomate, American Board of Internal Medicine 1993 – 1995 Resident in Internal Medicine, Department of Medicine, Brigham and Women's Hospital EMPLOYMENT: CURRENT POSTION 2015 - Present Director of the Duke-Margolis Center for Health Policy 2015 - Present Robert J. Margolis MD Professor of Business, Medicine and Health Policy 2015 - Present Faculty Member & Sr. Policy Advisor, University of Texas, Austin, Dell Medical School PREVIOUS POSITIONS 2007 – 2015 Senior Fellow in Economic Studies, Brookings Institution 2013 – 2015 Director, Initiatives on Value and Innovation in Health Care, Brookings Institution 2007 – 2013 Director, Engelberg Center for Health Care Reform, Brookings Institution 2006 – 2007 Visiting Senior Fellow, AEI-Brookings Joint Center for Regulatory Studies, American Enterprise Institute and the Brookings Institution 2004 – 2006 Administrator, Centers for Medicare and Medicaid Services, U.S. Department of Health and Human Services 2002 – 2004 Commissioner, U. S. Food and Drug Administration 2001 – 2002 Member, Council of Economic Advisers, and Senior Director for Health Care Policy, White House -
Daily Covid-19 Update
DAILY COVID-19 UPDATE January 6, 2021 WHAT HAPPENED TODAY LATEST STATISTICS First and foremost, today was an unprecedented day There are a total in Washington with the events in and around the U.S of 86,948,012 confirmed cases Capitol. That said, we did want to send out the Daily worldwide, 1,877,852 deaths and COVID-19 Update given that there were a number of 48,689,878 people have developments today. We hope everyone is staying recovered. safe. There are 21,213,347confirmed Despite a slow nationwide rollout of COVID-19 cases of the coronavirus in the vaccines, NIAID Director Dr. Anthony Fauci U.S. and 359,784 deaths. expressed optimism yesterday that the U.S. could soon begin giving out at least 1 million doses per LATEST PMJ day. He noted that it's "very possible" President-elect Joe Biden will fulfill his promise to administer 100 RESOURCES million vaccines within his first 100 days in office. Dr. Fauci added that 70% to 85% of Americans must be Drug Shortage and Medical vaccinated in order to achieve herd immunity, a goal Supply Chain Tracker he hopes to reach by September. Coronavirus State Reopening Additionally, Senate Minority Leader Chuck Schumer Tracker (D-NY) joined other Democratic leaders in support of $2,000 stimulus checks. He noted an increase in Lame Duck Preview Memo economic impact payments will be the first priority for the Senate if Democrats gain control of the chamber. President Trump EO Tracker Notably, the Senate runoff elections in Georgia COVID-19 Legislative Outlook resulted in Democratic candidates Raphael Warnock and Jon Ossoff defeating Kelly Loeffler and David State Responses to EO on Perdue, respectively. -
• President Donald Trump Dismissed Anthony Fauci's Dire Outlook For
COVID-19 6/19 UPDATE COVID-19 6/19 Update Global Total cases – 8,550,458 Total deaths – 456,881 United States Total cases – 2,205,307 Total deaths – 118,758 Total # tests – 25,403,498 Administration • President Donald Trump dismissed Anthony Fauci’s dire outlook for football this fall, saying the sport can be played safely but adding that he won’t watch if players resume protesting police brutality by kneeling during the national anthem • Wall Street banks should brace for their dividends to be influenced by adjustments to the annual stress tests that the Federal Reserve made due to the coronavirus pandemic, Fed Vice Chairman for Supervision Randal Quarles said Friday. o The exams help the Fed set the most important capital demands imposed on the largest U.S. lenders -- and they are instrumental for banks in setting shareholder dividends. While the tests have produced fewer shocks in recent years than in the period when they were initiated after the 2008 financial meltdown, next week’s results could see drama as the first to be calculated while a real crisis is raging. • Days before hosting a massive rally in Tulsa, Oklahoma, President Trump said in a Wall Street Journal interview that some people at the rally this Saturday may catch coronavirus, but added “it’s a very small percentage.” o The President's words come as Oklahoma is seeing a steady increase in its average of new confirmed cases per day. • The US Food and Drug Administration sent warning letters to three companies selling Covid-19 tests that the FDA says were “inappropriately” marketed and “potentially placing public health at risk.” o This is the first time the agency says it has sent warning letters to companies for marketing adulterated or misbranded test kits. -
Industry Profiles
MARKETLINE INDUSTRY PROFILES WHAT ARE MARKETLINE INDUSTRY PROFILES? MarketLine’s Industry Profiles are the ultimate go-to guide when you need reliable insights on a specific industry. Our Industry Profiles will help you to Each Industry Profile includes: Example titles: form a clear picture of individual sectors, • Forecasts for the market including who is operating within them Mining in Germany • Market value and volume data and how they are performing. • Industry segmentation Hot Drinks in China Concise and accurate, Industry Profiles • Macroeconomic analysis are presented within the globally • Competitor analysis recognized Porter’s Five Forces analysis • Leading company information framework to help you understand and We do the work for you... apply key insights in minutes. They are the ideal starting point for gaining a Profiling 2,500 individual industries, top-level understanding of individual MarketLine is one of the most prolific sectors across the globe. publishers of business information in the market. Industry Profiles are written exclusively by our expert analysts, drawing from their personal and professional expertise and primary and secondary research. HOW DID MARKETLINE GET THIS DATA? MarketLine Industry Profiles are written by our in-house analysts and prepared under an established methodology, 1. tried and tested over 10 years. PREPARATORY RESEARCH With stringent checks and controls to capture and validate the accuracy of our data, you can be confident in MarketLine to deliver quality data and insights. 2. 3. 4. 5. INDUSTRY EXTENSIVE REVIEW OF MODELING & QUALITY PROFILES SECONDARY IN-HOUSE FORECASTING CONTROL RESEARCH DATABASES WHY CHOOSE MARKETLINE? In an information-rich world, finding facts you can rely upon isn’t always easy.